N/A
Completed N=110
Optimizing PrEP Uptake & Adherence Among Male Sex Workers (MSW) Using a 2-stage Randomization Design
Prevention
Source: ClinicalTrials.gov NCT03086057 ↗
Enrolled (actual)
110
Serious AEs
0.0%
Results posted
Mar 2021
Primary outcomePrimary: Number of Participants With Verified Attendance at Initial Appointment at PrEP Clinic — 30; 13 Participants
Summary
"PrEPare for Work" is a two-stage randomized controlled pilot trial which utilizes a behavioral intervention to optimize the uptake and adherence of Pre-exposure Prophylaxis (PrEP) in Male Sex Workers (MSW).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Verified Attendance at Initial Appointment at PrEP Clinic |
30; 13 | — |
| PRIMARY Number of Participants Who Initiated PrEP |
26; 9 | — |
| PRIMARY Number of Participants Reporting Optimal PrEP Adherence |
5; 5 | — |
Eligibility Criteria
Inclusion Criteria
- 18 years of age or older
- Biological male at birth and current male gender identity
- Exchanged sex for money or drugs with another man in the past 3 months
- Report behavioral risk for HIV infection, consistent with Centers for Disease Control and Prevention guidelines for prescribing PrEP: condomless anal intercourse with at least one HIV-infected or unknown serostatus partner in the past three months
- HIV uninfected by antibody test* Stage 2
- Able to understand and speak English (for consent and counseling)
- Mental competency to provide voluntary informed consent
- Lives in the New England area
- Willing to initiate PrEP
Exclusion Criteria
- Unable to provide informed consent, including as a result of severe mental illness requiring immediate treatment or mental illness limiting the ability to participate
- HIV Positive at baseline
- Infected with Hepatitis B or diagnosed with renal insufficiency (glomerular filtration rate < 50) *Stage 2
- History of or current medical conditions that would preclude taking Truvada for PrEP *Stage 2
- Currently taking Truvada for PrEP
Data sourced from ClinicalTrials.gov (NCT03086057). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.